Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)

20/10/2017 9 min
Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)

Listen "Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)"

Episode Synopsis

Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.

More episodes of the podcast The Beacon (Audio)